Early Dose Projections of a HER2 Targeting Antibody

Human epidermal growth factor receptor 2, or HER2, is a protein overexpressed in some types of cancer. Trastuzumab is a monoclonal antibody that inhibits HER2 signaling by binding to the extracellular domain of HER2 and blocking dimerization with its binding partners.

This case study demonstrates how to use Applied BioMath Assess™ to make early human dose predictions of a HER2 targeting antibody such as Trastuzumab. 


View the video demo

Resource Type